<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<?properties manuscript?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-journal-id">0376441</journal-id>
<journal-id journal-id-type="pubmed-jr-id">6691</journal-id>
<journal-id journal-id-type="nlm-ta">Prog Brain Res</journal-id>
<journal-id journal-id-type="iso-abbrev">Prog. Brain Res.</journal-id>
<journal-title-group>
<journal-title>Progress in brain research</journal-title>
</journal-title-group>
<issn pub-type="ppub">0079-6123</issn>
<issn pub-type="epub">1875-7855</issn>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">30314565</article-id>
<article-id pub-id-type="pmc">6859061</article-id>
<article-id pub-id-type="doi">10.1016/bs.pbr.2018.07.007</article-id>
<article-id pub-id-type="manuscript">NIHMS1034766</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Opioid Modulation of Cognitive Impairment in Depression</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Jacobson</surname>
<given-names>Moriah L.</given-names>
</name>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Wulf</surname>
<given-names>Hildegard A.</given-names>
</name>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Browne</surname>
<given-names>Caroline A.</given-names>
</name>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Lucki</surname>
<given-names>Irwin</given-names>
</name>
</contrib>
<aff id="A1">Department of Pharmacology &amp; Molecular Therapeutics, Uniformed Service University, Bethesda, Maryland, 20814, USA</aff>
</contrib-group>
<author-notes>
<corresp id="CR1">Corresponding author: Dr. Caroline A. Browne, Department of Pharmacology &amp; Molecular Therapeutics, Uniformed Services University, 4301 Jones Bridge Road, Bethesda, MD 20814, Phone: 301-295-3248, <email>caroline.browne.ctr@usuhs.edu</email></corresp>
<fn fn-type="COI-statement" id="FN1">
<p id="P41"><bold>Conflict of interest:</bold> No conflict of interest.</p>
</fn>
</author-notes>
<pub-date pub-type="nihms-submitted">
<day>11</day>
<month>6</month>
<year>2019</year>
</pub-date>
<pub-date pub-type="epub">
<day>18</day>
<month>9</month>
<year>2018</year>
</pub-date>
<pub-date pub-type="ppub">
<year>2018</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>17</day>
<month>11</month>
<year>2019</year>
</pub-date>
<volume>239</volume>
<fpage>1</fpage>
<lpage>48</lpage>
<!--elocation-id from pubmed: 10.1016/bs.pbr.2018.07.007-->
<abstract id="ABS1">
<p id="P1">The failure of traditional antidepressant medications to adequately target cognitive impairment is associated with poor treatment response, increased risk of relapse and greater lifetime disability. Opioid receptor antagonists are currently under development as novel therapeutics for major depressive disorders (MDD) and other stress-related illnesses. Although it is known that dysregulation of the endogenous opioid system is observed in patients diagnosed with MDD, the impact of opioidergic neurotransmission on cognitive impairment has not been systematically evaluated. Here we review the literature indicating that opioid manipulations can alter cognitive functions in humans. Furthermore, we detail the preclinical studies that demonstrate the ability of mu opioid receptor (MOR) and kappa opioid receptor (KOR) ligands to modulate several cognitive processes. Specifically, this review focuses on domains within higher order cognitive processing, including attention and executive functioning, which can differentiate cognitive processes influenced by motivational state.</p>
</abstract>
<kwd-group>
<kwd>Opioids</kwd>
<kwd>cognition</kwd>
<kwd>depression</kwd>
<kwd>stress</kwd>
<kwd>antidepressants</kwd>
</kwd-group>
</article-meta>
</front>
</article>
</pmc-articleset>